Method of treating nash using a long-acting mutant human fibroblast growth factor
US12152059B2 · kind B2 · utility
0Cited by
2References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 23, 2019 |
| Grant date | Nov 26, 2024 |
| Priority date | — |
| Expiry date | Jul 23, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/1825
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH2—NαH-mFGF21, wherein mFGF21 consists of SEQ ID NO: 1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.